Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Eric Dein ericdeinmd
3 years 1 month ago
Abst0324 #ACR22
How close are we to measuring Interferon Signature in clinical practice?
NCounter and BioFire assays studied - correlated well we each other
Genes: IFI27, IFI44L, IFIT1, RSAD2
SLE higher than RA or FMS, but does not correlate with SLE activity
@RheumNow https://t.co/izpFtj9Pcd
Eric Dein ericdeinmd
3 years 1 month ago
Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE
Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls
AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis
@Rheumnow https://t.co/d98HSHnJVE
Eric Dein ericdeinmd
3 years 1 month ago
Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis
Factors for SLE transition: younger age, serositis, dsDNA
SSc transition: puffy finger, NFC, or SSc antibodies
No studies wo moderate or high risk of bias
Limited studies on biomarkers for SLE, need more studies
@Rheumnow https://t.co/GofGF8TkCx
Eric Dein ericdeinmd
3 years 1 month ago
All monster stories end with an unexpected award: A new order
@cuttingforstone at #ACR22 tells the monster story of #covid
“How will history review our story?”
The science will get an A+, but we failed to learn the lessons of history
All was predictable through history
@RheumNow
Eric Dein ericdeinmd
3 years 1 month ago
Year in Review #ACR22
GLORIA
Low steroid usage: lower DAS28, reduced joint damage
BUT 24% increased adverse effects
@RheumNow https://t.co/vYTAhoQEqr
Eric Dein ericdeinmd
3 years 1 month ago
Ab1012 #ACR22
@AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS
21% PsA pts on opioids, 27% AS on opioids
Opioid users - more co-morbidities, 🚬, worse disease
Tended to higher use of anti-rheumatic drugs
Higher health care utilizations, medical $$
@RheumNow
Eric Dein ericdeinmd
3 years 1 month ago
@RheumNow Panel felt that weight and smoking recs were adequately covered by general health recommendations
BUT, this misses a HUGE opportunity to stress that inflammatory arthritis pts have higher risks and need greater emphasis on modifiable risk factors than gen pop
#ACR22 @RheumNow
Dr. Rachel Tate uptoTate
3 years 1 month ago
CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc
David Liew drdavidliew
3 years 1 month ago
Look at these graphs and try and tell me that sex and gender doesn't matter in RA.
We have seen in study after study after study - sex and gender matters.
ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN
David Liew drdavidliew
3 years 1 month ago
New IgG4-RD therapeutic avenues,
mechanistically driven (B cell-CTL interaction):
inebilizumab: registered for NMO, ph3 now
obexelimab: novel dual MOA ?safer, ph3 now
rilzabrutinib: BTKi, ph2 now
elotuzumab: targets SLAMF7, MM registered, NIH study
John Stone #ACR22 @RheumNow https://t.co/lx4bnCutlS
David Liew drdavidliew
3 years 1 month ago
Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H
David Liew drdavidliew
3 years 1 month ago
One of the nicest, smartest, and hardest working young rheumatologists you will meet, and I'm sure is destined for great things. My hat off to you @SattuiSEMD, congratulations!
#ACR22 @RheumNow https://t.co/dzHXeahsHT
David Liew drdavidliew
3 years 1 month ago
Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe?
Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so
Much more to understand across tumor streams
ABST0760 #ACR22 https://t.co/z1rhAJZ9gj
Poster Hall